Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

doi:10.1053/j.gastro.2015.05.010

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Gastroenterology - 1 Sept 2015

Charlton Michael, Everson Gregory T, Flamm Steven L, Kumar Princy, Landis Charles, Brown Robert S, Fried Michael W, Terrault Norah A, O'Leary Jacqueline G, Vargas Hugo E, Kuo Alexander, Schiff Eugene, Sulkowski Mark S, Gilroy Richard, Watt Kymberly D, Brown Kimberly, Kwo Paul, Pungpapong Surakit, Korenblat Kevin M, Muir Andrew J, Teperman Lewis, Fontana Robert J, Denning Jill, Arterburn Sarah, Dvory-Sobol Hadas, Brandt-Sarif Theo, Pang Phillip S, McHutchison John G, Reddy K Rajender, Afdhal Nezam

Abstract excerpt

BACKGROUND & AIMS: There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. METHODS: In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuvir, and ribavirin in patients infected with HCV genotypes 1 or 4. Cohort A enrolled patients with cirrhosis and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholestasis, Intrahepatic

Share to Drug Combinations

Share to Fluorenes

Share to Liver Transplantation

Share to Ribavirin

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Open in PubMed

Identifiers

PMID: 25985734
DOI: 10.1053/j.gastro.2015.05.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.PMID 25985734Read ↗

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.Semantic proximity Read ↗

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.Semantic proximity Read ↗

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.Semantic proximity Read ↗

Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.Semantic proximity Read ↗

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.Semantic proximity Read ↗

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.Semantic proximity Read ↗

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.Semantic proximity Read ↗

Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.Semantic proximity Read ↗

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.Semantic proximity Read ↗

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).Semantic proximity Read ↗

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.Semantic proximity Read ↗

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.